Vesugen

PeptideXpo buyer fit

Overview

Vesugen is a Khavinson-class tripeptide bioregulator with the sequence Lys-Glu-Asp (KED), positioned within the Khavinson framework as the vascular endothelial regulatory peptide. The KED sequence is distinct from the tetrapeptide-family members (AEDG / AEDL / AEDP) in that it is a three-residue rather than four-residue peptide and includes a basic N-terminal lysine, both features shifting its biophysical profile from the AEDx tetrapeptide siblings. Vesugen is studied in research workflows examining vascular endothelial gene-expression programs, angiogenesis-related signaling, and cardiovascular tissue maintenance within the Khavinson bioregulator framework. PeptideXpo supplies Vesugen as a lyophilized 10 mg vial at ≥99.0% HPLC purity. As a tripeptide, Vesugen is simpler analytically than the tetrapeptide siblings, the molecular weight (392 g/mol theoretical) is distinct from the AEDx tetrapeptide family and mass-spec confirmation alone is generally sufficient for identity. Sequence verification by LC-MS/MS is available on request.

Who buys this, and why

Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

Not consistently registered; see batch COA

Sequence

KED

Appearance

White lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

10 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 2 minutes

MOQ

On request

Lead time

14–21 days

Storage

2–8°C, protect from light

Documentation available on request

• Certificate of Analysis (COA)
• Ratio-verification HPLC
• Mass-spec identity of each component
• Stability of the blend (matrix-specific)
• Bacterial endotoxin (LAL, USP <85>)
• Sterile-fill documentation (where applicable)
• SDS / MSDS
• Private-label / OEM specification sheet

Regulatory note

Khavinson bioregulator; CAS commonly not registered. Confirm KED sequence and identity per batch COA.

Selected literature

1. Khavinson VKh, Tarnovskaia SI, Lin'kova NS, Guton EO, Elashkina EV. [Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging]. Adv Gerontol. 2014;27(1):108-114.
2. Khavinson VKh, Lin'kova NS, Evlashkina EV, Durnova AO, Kozlov KL, Gutop OE. Molecular aspects of anti-atherosclerotic effects of short peptides. Bull Exp Biol Med. 2014;158(1):159-163.
3. Kozlov KL, Bolotov II, Linkova NS, Drobintseva AO, Khavinson VKh, Dyakonov MM, Kozina LS. [Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis]. Adv Gerontol. 2016;29(4):646-650.
4. Chalisova NI, Lopatina NG, Kamishev NG, Linkova NS, Koncevaya EA, Dudkov AV, Kozina LS, Khavinson VKh, Titkov YuS. Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells. Bull Exp Biol Med. 2012;153(4):569-572.
5. Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012;153(1):148-151.
6. Khavinson VKh, Lin'kova NS, Umnov RS. Peptide KED: molecular-genetic aspects of neurogenesis regulation in Alzheimer's disease. Bull Exp Biol Med. 2021;171(2):190-193.

Frequently asked questions